Expression quantitative trait locus (eQTL) mapping provides a powerful means to identify func-65 tional variants influencing gene expression and disease pathogenesis. We report the identification 66 of cis-eQTLs from 7,051 post-mortem samples representing 44 tissues and 449 individuals as part 67 of the Genotype-Tissue Expression (GTEx) project. We find a cis-eQTL for 88% of all annotated 68 protein-coding genes, with one-third having multiple independent effects. We identify numerous 69 tissue-specific cis-eQTLs, highlighting the unique functional impact of regulatory variation in di-70 verse tissues. By integrating large-scale functional genomics data and state-of-the-art fine-mapping 71 algorithms, we identify multiple features predictive of tissue-specific and shared regulatory effects. 72 We improve estimates of cis-eQTL sharing and effect sizes using allele specific expression across tis-73 sues. Finally, we demonstrate the utility of this large compendium of cis-eQTLs for understanding 74 the tissue-specific etiology of complex traits, including coronary artery disease. The GTEx project 75 provides an exceptional resource that has improved our understanding of gene regulation across 76 tissues and the role of regulatory variation in human genetic diseases. 77 Introduction 78 Genome-wide association studies (GWAS) have identified a wealth of genetic variants associated 79 with complex traits and disease risk. However, characterizing the molecular and cellular mechanisms 80 through which these variants act remains a major challenge that limits our understanding of disease 81 pathogenesis and the development of therapeutic interventions. Expression quantitative trait locus 82 (eQTL) studies provide a systematic approach to characterize the molecular consequences of genetic 83 variation across tissues and cell types 1-4 . Multiple studies have identified eQTLs for thousands of 84 genes 5-7 , providing novel insights into gene regulation and enabling the interpretation of GWAS 85 signals 8-12 . These studies have largely been performed in a few easily accessible cell types and cell 86 lines, precluding interpretation of the systemic and tissue-specific consequences of genetic variation.
very strong shared associations (P < 10 −10 in each tissue), roughly 10% exhibited different single 137 top gene associations across tissues, indicating that the interpretation of the regulatory effect of 138 these variants can still be tissue-dependent ( Fig. 2b ).
139
To quantify the impact of sample size and number of tissues studied on cis-eQTL discovery, we 140 first compared eGene discovery across a range of sample sizes and tissues (Fig. 2c ). The discovery 141 of new eGenes was most influenced by sample size. However, a diverse sampling of tissues also 142 improved eGene discovery. At its full sample size of 256 individuals, tibial nerve had the most cis-eQTLs discovered in GTEx tissues with large sample sizes were less likely to be shared in other 148 tissues, indicating that weaker associations identified in deeply sampled tissues remain difficult to 149 replicate due to their smaller and possibly tissue-specific effects (Fig. 3; Extended Data Fig. 5 Pairwise π 1 statistics are reported for single-tissue eQTL discoveries in each tissue. Higher π 1 values indicate an increased replication of eQTLs. Tissues are grouped using hierarchical clustering on rows and columns separately with a distance metric of 1 − ρ, where ρ is the Spearman correlation of π 1 values. π 1 is only calculated when the gene is expressed and testable in the replication tissue. (b) Proportion of variants with top associated protein-coding gene preserved between tissues shown for varying nominal association thresholds. (c) eGene discovery as a function of sample size and number of tissues assayed. Each tissue was subsampled to 70, 100, and 150 individuals and a greedy algorithm was used to assess sequential combinations of tissues that maximize the total number of unique eGenes discovered.
patterns across tissues [16] [17] [18] . We performed a meta-analysis across all 44 tissues using METASOFT 19 153 and identified between 4,538 and 9,327 eGenes (m-value ≥ 0.9) per tissue. On average, each cis-154 eQTL effect was shared across 15 tissues. The advantage of meta-analysis was most apparent 155 for individual tissues with smaller sample sizes ( Fig. 3a) , most notably for the 10 sampled brain 156 regions. For example, in the hippocampus (N = 81), the number of single-tissue eGenes is 847 157 whereas the number of eGenes detected through meta-analysis is 4,636. eGenes identified by meta-158 analysis were more likely to be significant in single tissue analyses at larger sample sizes (Extended 159 Data Fig. 6 ). Our meta-analysis approach demonstrates that sharing of cis-eQTL effects across 160 multiple tissues can improve discovery in specialized or difficult-to-access tissues.
161
To ensure these findings did not depend on the modeling assumptions of METASOFT, we an- 
169
Modeling of cis-eQTL sharing across tissues using METASOFT showed a bimodal pattern with 170 increasing tissue-specificity for tissues with larger sample sizes ( Fig. 3b ). Increased tissue-specificity 171 likely emerges from differences in discovery power and effect sizes across tissues. It also suggests 172 that deep sampling diminishes the gains of meta-analysis, instead benefiting identification of more 173 tissue-specific effects. The bimodal pattern of sharing was further supported by three different which are known to be particularly relevant for disease associations 22-24 .
200
Integration of genomic annotations in eQTL testing has been demonstrated to improve power 6, 25-27 .
201
We applied a Bayesian hierarchical model incorporating variant-level genomic annotations for eQTL 202 discovery in 26 tissues with cell-type matched annotations from the Epigenomics Roadmap 28 (Wen, 203 X. submitted). Distance to the TSS and promoter and enhancer annotations improved our ability 204 to discover eQTLs (Extended Data Fig. 10a ). Using these annotations increased the total number 205 of eGene discoveries by an average of 43% (1,200 genes) across tissues (Extended Data Fig. 10b ).
206

Fine-mapping eQTL variants 207
To identify likely causal variants underlying eQTLs, we applied two computational fine-mapping 208 strategies. First, we identified 90% credible sets for each eGene in each tissue using CAVIAR 29 , a 209 probabilistic method that utilizes the observed marginal test statistics and LD structure to detect 210 variant sets that may harbor more than one causal variant 29 . Across all tissues, the mean credible 211 set size was 29 variants (per tissue means ranged from 25 to 31). Credible set size decreased with 212 increasing discovery tissue sample size. The addition of 100 samples reduced credible set size by an 213 average of one variant indicating that large sample sizes are required to identify causal variants using 214 association strength alone (Extended Data Fig. 11a ). As expected, credible sets overlapped across 215 tissues more extensively for tissue-shared eQTLs compared to tissue-specific eQTLs (Extended 216 Data Fig. 11b ).
217
We estimated the probability that each eVariant is a causal variant using CaVEMaN, a non-218 parametric sampling-based approach that accounts for noise in expression measurements and linkage 219 structure (Brown et al. in preparation) . Across tissues, we estimated that between 3.5%-11.7% 220 of primary eVariants are causal (probability ≥ 0.8; Extended Data Fig. 12 ). For predicted causal 221 variants, the same variant is predicted as causal for 13.3% to 32.6% of variants at the same proba-222 bility threshold in separate tissues where an eGene is also identified. However, the replication rate 223 π 1 was considerably higher (59.6%-93.5%), demonstrating the difficulties in fine mapping variants 224 even when the LD structure is expected to be preserved across tissues. . 4a ).
234
As expected, mean effect sizes per tissue were influenced by sample size (Extended Data Fig. 13 ).
235
When stratifying each gene by the number of tissues that it is expressed in, we observed a decrease 236 in the average effect size per gene indicating that genes expressed in multiple tissues are less likely 237 to have eQTLs with large regulatory effects (Spearman ρ = −0.29, P < 2.2 × 10 −16 , Fig. 4b ). Figure 3 . Multi-tissue eQTL discovery and genomic context. (a) The proportion of expressed genes for which eGenes are discovered in single tissues (5% FDR; small dots) and the multi-tissue meta-analysis (m-value ≥ 0.9; large dots), stratified by the sample size of individual tissues. In the meta-analysis, eQTL discoveries are made using METASOFT to identify tissues where the posterior probability a given eQTL effect exists (i.e. the tissue's m-value) is ≥ 0.9. (b) The number of tissues in which a given eQTL is shared as a function of tissue sample size. For each tissue, we calculated the degree of sharing (i.e. the number of tissues with m-value ≥ 0.9) for all eQTLs identified in that tissue at a 5% FDR. Tissues were then binned into quartiles based on sample size. The median number of shared tissues is plotted for each quartile as a horizontal black line. (c) Enrichment of eVariants in cis-regulatory elements (CREs) across 128 NIH Epigenomics Roadmaps cell types is depicted for each GTEx discovery tissue. Stronger enrichment was observed in matched tissues (colored dots) compared to unmatched tissues (boxplots). (d) Proportion of eQTLs that are shared between two tissues (m-value in both tissues ≥ 0.9) if the eVariant overlaps the same Roadmap annotation in both tissues (y-axis) or different annotations (x-axis). Points represent the mean of pairwise comparisons between all tissues, colored by the discovery tissue. (e) Enrichment of eVariants in tissue-matched enhancers (white) and promoters (grey) for the first four conditionally independent eQTLs discovered for each eGene (x-axis, sorted by discovery order). (f) Proportion of eVariants overlapping tissue-matched DNAse I hypersensitive sites as a function of the probability that a variant is causal. Points are colored by the eQTL discovery tissue. shared eQTLs matched for significance level (Wilcoxon rank sum test, P < 2.2 × 10 −16 , Fig. 4c ; 240 Extended Data Fig. 13 ).
241
We assessed whether variants with distinct functional annotations had different average effects 242 on gene expression using the large number of eQTLs we discovered. eVariants at canonical splice We observed that 92.7% of all common variants assayed by GTEx are nominally associated with 289 the expression of one or more genes in one or more tissues (P < 0.05) and nearly 50% are significant 290 when performing a Bonferroni correction based on the number of tissues tested (Fig. 5b) . Given plied GTEx to the PHACTR1 locus which is associated with a range of complex traits, including 297 myocardial infarction (MI) 35 , coronary artery disease (CAD) 36-38 , cervical artery dissection 39 , and 298 migraines 40 (Fig. 5c) . Notably, the CAD and MI risk allele (G) at rs9349379 is protective for cer-299 vical artery dissection and migraines. Initial targeted analyses 41 demonstrated that the CAD risk 300 allele (G) at rs9349379 is associated with decreased expression of PHACTR1 in coronary arteries.
301
To investigate the mechanism and tissue of action of this pleiotropic SNP, we characterized 302 the effect of rs9349379 across the 44 GTEx tissues. rs9349379G was strongly associated with 303 decreased PHACTR1 expression ( Fig. 5e ; meta-analysis P < 2.2 × 10 −16 ), with a tissue-specific 304 eQTL effect observed only in aorta, coronary, and tibial arteries (Fig. 5e; m-value ≥ 0.9) , where 305 the risk allele expression is 72%, 57% and 65% of the protective allele expression, respectively. 306 PHACTR1, TBC1D7, and the nearby noncoding RNA, RP1-257A7.5, were the only genes within 307 1 Mb associated with genotype at rs9349379 in any tissue. Notably, the tissue specificity of the 308 eQTL effect was not mirrored in the tissue specificity of PHACTR1 gene expression (Extended 309 Data Fig. 17 ). Colocalization analysis in arterial tissues indicated that rs9349379 is likely the 310 variant responsible for both the GWAS and the eQTL signal in the locus (Fig. 5f ; RTC = 1, 311 eCAVIAR = 0.95) 34, 42 . Applying the PrediXcan method 12 to the BioVU repository 43 , we found 312 that genetically predicted decreased PHACTR1 expression in coronary and aorta arteries was 313 associated with tachycardia (meta-analysis P < 10 −6 ), whereas genetically predicted increased 314 PHACTR1 expression was associated with migraines (P = 1.2 × 10 −7 ). PHACTR1 is the sole 315 gene in the locus that was implicated by PrediXcan in BioVU, using arterial tissues, for either 316 trait. These results suggest that the pleiotropic effects of rs9349379 are driven by a consistent, 317 tissue-specific molecular phenotype that causes diverse downstream consequences.
318
Discussion
319
The most immediate effects of functional genetic variation are on molecular phenotypes. Combining 320 trait and disease associated variants with molecular QTL data has been a successful strategy for 321 resolving causal genes and tissues 44 . In particular, these approaches have provided key information 322 on human-specific traits and therapeutic interventions 11, 45, 46 . While the pilot phase of the GTEx 323 project identified cis-eQTLs in nine tissues, the GTEx V6p collection has been expanded to 44 324 tissues providing a wealth of additional cis-eQTL discoveries. These data facilitate both systematic 325 and targeted interpretation of the functional consequences of genetic variants across a range of 326 biological contexts. 327 We found a pervasive effect of common regulatory variation on the vast majority of human 328 genes with a sizable proportion of genes having multiple independent loci associated with their 329 expression levels. By combining cis-eQTL data across tissues, we demonstrated that GTEx V6p 330 data may be used to enable cis-eQTL discovery in tissues with limited sample sizes. Many of the 331 largest, primary effects are shared across tissues. Additionally, we observed that both secondary 332 cis-eQTLs and cis-eQTLs from deeply sampled tissues exhibit more tissue-specificity. cis-eQTLs can only be identified through broad tissue sampling.
cis-eQTL effect size is represented in log 2 scale as s = log 2 k, and is capped at 100-fold to 525 avoid outliers (|s| < log 2 100). Expression counts were retrieved for all top eGenes in all tissues 526 and PEER corrected. Data was log-transformed with one pseudo-count to stabilize the variance.
527
The model was fit using non-linear least squares to derive maximum likelihood estimates of the we generated a single-signal expression phenotype by controlling for all covariates fitted in the cis-557 eQTL mapping and all other eVariants for the gene except the eVariant whose signal we wished 558 to preserve. These data were sampled with replacement 10,000 times and cis-eQTL mapping was 559 performed on each resample. The proportion of times a given eVariant was ranked i was calculated, 560 denoted F i . The CaVEMaN score is then defined as 10 with probability ρ. To define these credible sets in each tissue, we used a threshold of ρ = 90%. 574 We utilized eCAVIAR (eQTL and GWAS CAVIAR) to colocalize GWAS and eQTL studies for 575 detection of the target genes and relevant tissues 42 . eCAVIAR computes a posterior probability 576 of a variant identified as causal in both GWAS and eQTL studies. We used a cut-off of 1% for 577 colocalization posterior probability based on observations from previous simulations 42 .
578
To test for a significant relationship between tissue sample size and the size of the 90% credible 579 set, we compared credible set sizes for the top 100 single-tissue cis-eQTLs across tissues (Extended 580 Data Fig. 11a ). We further combined cis-eQTL sharing results from METASOFT with CAVIAR's 581 90% credible sets to test if tissues with shared cis-eQTLs could be used to fine-map the causal 582 variant. Here, from the initial METASOFT results, we identified the top shared cis-eQTL for each 583 eGene by selecting the cis-eQTL with the smallest RE2 P -value. For eGenes that had a shared 584 cis-eQTL or a tissue-specific cis-eQTL, we compared the intersection of the 90% credible sets within 585 and between each group (Extended Data Fig. 11b ).
586
Overlap of tissue-specific and tissue-shared eGenes with disease genes 587 For each gene tested for multi-tissue eQTLs using METASOFT, we calculated the proportion 588 of tissues for which the gene had a strong eQTL effect (i.e. the proportion of tissues with m-589 value ≥ 0.9). We defined tissue-specific eGenes as genes in the bottom 10% of the empirical 590 distribution of this proportion. Similarly, we defined tissue-shared eGenes as genes in the top 10% 591 of this distribution. We examined the enrichment of tissue-specific and tissue-shared eGenes in 592 six different gene lists: the NHGRI-EBI GWAS Catalog 62 , the Online Mendelian Inheritance in 593 Man (OMIM) database 63 , the Orphanet database, the ClinVar database 64 , the list of genes with cis-regulatory elements suggests mechanisms underlying cell type specificity of eQTLs. PLoS
